ResearchCLINICALTRIALSYesterday
Researchers completed a large study of 13,770 patients with chronic inflammatory diseases (like rheumatoid arthritis and other autoimmune conditions) to understand how COVID-19 affected them. The study, led by a hospital in France, was designed to track whether patients taking medications for their autoimmune diseases had worse outcomes if they caught COVID-19. This trial has now finished collecting data.
WHY IT MATTERSIf you have an autoimmune or inflammatory disease, this completed trial provides real-world evidence about COVID-19 risk in your population—information that can help you and your doctor make informed decisions about infection prevention and disease management.
ResearchCLINICALTRIALSMay 5
Joined Bio is recruiting 100,000 people—both healthy individuals and those with conditions like lupus, celiac disease, and kidney disease—to participate in a research study. Participants will share health information, lifestyle details, blood or tissue samples, and feedback with researchers. This information will help scientists develop better tests, treatments, and cures for various diseases.
WHY IT MATTERSIf you have lupus, celiac disease, or chronic kidney disease, enrolling could directly contribute to research that develops better diagnostic tools and treatments specifically for your condition.
ResearchRSSApr 27
A new study found that women with Parkinson's disease are much less likely than men to choose a brain surgery called deep brain stimulation (DBS). The main reason is that women often worry about being a burden on their family and don't have as much support available to help them through the procedure and recovery.
WHY IT MATTERSIf you're a woman with Parkinson's considering DBS, understanding that support concerns are common may help you have more honest conversations with your doctor and family about what you actually need to move forward with treatment.
ResearchRSSApr 22
Scientists at Florida International University found a compound called CTS2444-32 that may help slow Parkinson's disease by improving how mitochondria (the energy centers of cells) work. The compound works by reducing a protein called DRP1 that controls mitochondrial function, which helps prevent toxic proteins from building up in the brain—a key problem in Parkinson's.
WHY IT MATTERSIf CTS2444-32 proves effective in human trials, it could offer Parkinson's patients a new treatment option that targets the disease's underlying cause rather than just managing symptoms.
ResearchRSSApr 22
Researchers found that a Parkinson's disease medication called Crexont helped patients spend more time feeling better and less time experiencing symptoms when they switched from other levodopa treatments. The study showed improvements in movement control and daily functioning across different patient groups. This is early-stage research being presented at a medical conference.
WHY IT MATTERSIf you take levodopa for Parkinson's and struggle with 'off' periods when symptoms return between doses, Crexont may offer a way to extend your good symptom control time throughout the day.